Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 9/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 8/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309658 | 0.85 | ITGAL (0.52) | ITGALITGB2ICAM1L3MBTL1RAB9A | |
| SCHEMBL6317023 | 0.84 | ITGAL (0.51) | ITGALITGB2ICAM1L3MBTL1RAB9A | |
| SCHEMBL6317720 | 0.84 | ITGAL (0.51) | ITGALITGB2ICAM1L3MBTL1RAB9A | |
| SCHEMBL6568431 | 0.79 | ITGAL (0.68) | ITGALITGB2ICAM1ALDH1A1L3MBTL1 | |
| SCHEMBL6310695 | 0.79 | ITGAL (0.68) | ITGALITGB2ICAM1ALDH1A1L3MBTL1 | |
| SCHEMBL6318617 | 0.78 | RAB9A (0.49) | ITGALITGB2ICAM1ALDH1A1L3MBTL1 | |
| SCHEMBL6919943 | 0.78 | ITGAL (0.52) | ITGALITGB2ICAM1RAB9APOLB | |
| SCHEMBL6317608 | 0.77 | RAB9A (0.48) | ITGALITGB2ICAM1L3MBTL1RAB9A | |
| SCHEMBL6310203 | 0.76 | ITGAL (0.49) | ITGALITGB2ICAM1RAB9APOLB | |
| SCHEMBL13982755 | 0.72 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1LMNAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | ITGAL 57/4885ITGB2 32/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.